Trade Report: The Esperion Therapeutics Inc. (ESPR) Given a $13.00 Price Target by Chardan Capital Analysts

The Esperion Therapeutics Inc. (ESPR) Given a $13.00 Price Target by Chardan Capital Analysts

Chardan Capital set a $13.00 price target on Esperion Therapeutics Inc. (NASDAQ:ESPR) in a research note released on Thursday. The brokerage currently has a a hold rating on the biopharmaceutical company’s stock.

ESPR has been the subject of several other reports. Barclays PLC lowered Esperion Therapeutics from an overweight rating to an equal weight rating and dropped their target price for the company from $28.00 to $13.00 in a research note on Wednesday, June 29th. Lake Street Capital lowered their price target on Esperion Therapeutics from $80.00 to $27.00 and set a buy rating for the company in a research report on Wednesday, June 29th. Vetr raised Esperion Therapeutics from a buy rating to a strong-buy rating and set a $12.60 price target for the company in a research report on Monday, August 1st. Credit Suisse Group AG downgraded Esperion Therapeutics from a neutral rating to an underperform rating and lowered their price target for the company from $23.00 to $10.00 in a research report on Wednesday, June 29th. Finally, JMP Securities reissued a buy rating and set a $67.00 price target on shares of Esperion Therapeutics in a research report on Thursday, June 16th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have assigned a buy rating to the stock. Esperion Therapeutics presently has an average rating of Buy and a consensus price target of $28.54.

Esperion Therapeutics (NASDAQ:ESPR) traded down 5.496% during midday trading on Thursday, reaching $12.295. The company’s stock had a trading volume of 211,579 shares. The company has a 50 day moving average of $12.29 and a 200-day moving average of $13.98. The company’s market capitalization is $277.25 million. Esperion Therapeutics has a 1-year low of $9.58 and a 1-year high of $30.41.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.16. During the same period last year, the business earned ($0.55) earnings per share. Equities research analysts anticipate that Esperion Therapeutics will post ($3.37) earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. ProShare Advisors LLC increased its position in shares of Esperion Therapeutics by 1.3% in the second quarter. ProShare Advisors LLC now owns 18,533 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 238 shares in the last quarter. Stifel Financial Corp boosted its stake in shares of Esperion Therapeutics by 10.6% in the second quarter. Stifel Financial Corp now owns 15,017 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 1,438 shares during the last quarter. Swiss National Bank boosted its stake in shares of Esperion Therapeutics by 7.2% in the second quarter. Swiss National Bank now owns 22,200 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 1,500 shares during the last quarter. Teachers Advisors Inc. boosted its stake in shares of Esperion Therapeutics by 10.0% in the second quarter. Teachers Advisors Inc. now owns 21,380 shares of the biopharmaceutical company’s stock valued at $211,000 after buying an additional 1,942 shares during the last quarter. Finally, California State Teachers Retirement System boosted its stake in shares of Esperion Therapeutics by 8.1% in the second quarter. California State Teachers Retirement System now owns 30,016 shares of the biopharmaceutical company’s stock valued at $297,000 after buying an additional 2,251 shares during the last quarter. 65.22% of the stock is owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Related posts

Leave a Comment